Allogene Therapeutics (ALLO) Return on Sales [ROS] (2021 - 2026)
Allogene Therapeutics' Return on Sales [ROS] came in at -1011.21% for Q2 2026.
Powered by 
Analysis
Allogene Therapeutics (ALLO) Return on Sales [ROS] (2021 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Allogene Therapeutics reported Return on Sales [ROS] of -3886.14%; for FY2024, it was -1241813.64%, down 896827.32 percentage points from FY2023.
- Return on Sales [ROS] has declined in each of the last three years, with a three-year change of -1241655.70 percentage points (FY2021 to FY2024).
- Going back by year, Return on Sales [ROS] was -344986.32% in FY2023 (-129899.14 pp), -215087.18% in FY2022 (-214929.24 pp) and -157.94% in FY2021.
- The Q2 2026 figure represents the highest quarterly Return on Sales [ROS] since Q4 2021.
- The fastest year-over-year change in Return on Sales [ROS] over five years came in Q2 2022 (a gain of 41717.05 percentage points), and the weakest in Q4 2024 (a drop of 836532.68 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 34.46% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 24.35% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 36.01% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 30.74% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 29.12% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 35.79% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 41.71% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 32.98% |
| 10 | Allogene Therapeutics | 322.04 Mn | -820.62 Mn | - | -4,099.33% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -4,099.33% |
| Jun 30, 2026 | -1,011.21% |
| Mar 31, 2025 | -1,263,181.82% |
| Sep 30, 2024 | -692,600.00% |
| Jun 30, 2024 | -444,676.92% |
| Mar 31, 2024 | -315,927.27% |
| Dec 31, 2023 | -405,280.95% |
| Sep 30, 2023 | -286,345.45% |
| Jun 30, 2023 | -366,090.91% |
| Mar 31, 2023 | -330,306.67% |
| Dec 31, 2022 | -370,750.00% |
| Sep 30, 2022 | -305,596.30% |
| Jun 30, 2022 | -119,712.50% |
| Mar 31, 2022 | -205,164.10% |
| Dec 31, 2021 | 2.26% |
| Sep 30, 2021 | -158,510.20% |
| Jun 30, 2021 | -161,429.55% |
| Mar 31, 2021 | -86.58% |
API Access
Allogene Therapeutics Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=ALLO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "ALLO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=ALLO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();